The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

January 10, 2020

Floor J. Backes, MD, discusses the consideration of financial toxicity when choosing a PARP inhibitor for a patient with ovarian cancer.

January 10, 2020

Jonathan E. Brammer, MD, discusses the importance of achieving minimal residual disease negativity in relapsed/refractory acute lymphoblastic leukemia.

January 09, 2020

Alice Mims, MD, discusses biomarker research and therapeutic developments in acute myeloid leukemia.

January 09, 2020

Floor J. Backes, MD, discusses the phase III FILM trial in endometrial cancer.

January 09, 2020

Jonathan E. Brammer, MD, discusses the role of minimal residual disease and transplant in acute lymphoblastic leukemia, as well as the introduction of CAR T-cell therapy and other novel agents to the armamentarium.

January 09, 2020

Alice S. Mims, MD, discusses up front molecular profiling in patients with newly diagnosed acute myeloid leukemia.

January 09, 2020

Maria Chaudhry, MBBS, discusses unmet needs in relapsed/refractory multiple myeloma.

January 08, 2020

Jennifer A. Woyach, MD, discusses the evolving treatment paradigm and sequencing challenges in chronic lymphocytic leukemia.

January 08, 2020

David O’Malley, MD, discusses remaining questions in the ovarian cancer field.

January 07, 2020

Maria Chaudhry, MBBS, discusses recent and ongoing research in newly diagnosed and relapsed/refractory multiple myeloma.

January 07, 2020

Maria Chaudhry, MBBS, discusses the use of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone in transplant-ineligible patients with multiple myeloma.

January 07, 2020

Jennifer Woyach, MD, discusses the results of the ELEVATE-TN trial in patients with treatment-naïve chronic lymphocytic leukemia.

January 03, 2020

Jennifer Woyach, MD, discusses frontline treatment options for patients with chronic lymphocytic leukemia.

January 01, 2020

OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.

December 16, 2019

Casey M. Cosgrove, MD, discusses later-line treatments in ovarian cancer and ongoing research.

December 11, 2019

John Hays, MD, PhD, discusses the potential for PARP inhibitor combinations in patients with ovarian cancer.

November 22, 2019

Ritu Salani, MD, discusses considerations for neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.

November 22, 2019

John Hays, MD, PhD, discusses ongoing research with immunotherapy in ovarian cancer, challenges with determining predictive biomarkers of response, and promising emerging modalities.

November 21, 2019

Larry J. Copeland, MD, discusses how therapy for patients with ovarian cancer has evolved in recent years.

November 21, 2019

Ritu Salani, MD, discusses the potential of targeted therapy and immunotherapy in cervical cancer.